Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT
=======================================================================================================================================================================

* Annah S Rolig
* Daniel C Rose
* Grace Helen McGee
* Werner Rubas
* Saul Kivimäe
* William L Redmond